论文部分内容阅读
新近,Holmgren等报告“第二代”新肿瘤标记抗原CA50.该标记与CA19-9一样,是涎神经节苷脂.作者检验新肿瘤标记的准确性,并将其与至今在胃肠道疾病,特别是胰腺癌诊断中应用的CA19-9作比较.患者和方法:208例患者(女,85,男123),年龄22～28岁,均于禁食12小时后晨间测定其血清CA19-9和CA50.分三组:1.对照组38例(女21,男17)无胃肠病和恶性疾病.2.上消化道良性病组:110例(女41,男69) 其中急性胰腺炎18例,慢性胰腺炎40例,总胆管结石21例,肝硬化31例(27例为营养
Recently, Holmgren et al. reported that “second generation” new tumor marker antigen CA50. This marker, like CA19-9, is a ganglioside glycoside. The authors tested the accuracy of the new tumor marker and compared it with that in the gastrointestinal tract. Diseases, especially CA19-9 for diagnosis of pancreatic cancer were compared. Patients and Methods: 208 patients (female, 85, male 123), aged 22 to 28 years old, all measured 12 hours after fasting Serum CA19-9 and CA50. were divided into three groups: 1. Control group 38 cases (female 21, male 17) without gastrointestinal disease and malignant disease. 2. Upper gastrointestinal benign disease group: 110 cases (female 41, 69 males) There were 18 cases of acute pancreatitis, 40 cases of chronic pancreatitis, 21 cases of total bile duct stones, and 31 cases of cirrhosis (27 cases of nutrition